178 related articles for article (PubMed ID: 18651863)
1. Development of differential diagnosis for benign and malignant pheochromocytomas.
Gao B; Kong F; Xu Z
Int J Urol; 2008 Sep; 15(9):771-7. PubMed ID: 18651863
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic management of benign and malignant pheochromocytoma.
Scholz T; Schulz C; Klose S; Lehnert H
Exp Clin Endocrinol Diabetes; 2007 Mar; 115(3):155-9. PubMed ID: 17427102
[TBL] [Abstract][Full Text] [Related]
3. Candidate genes associated with malignant pheochromocytomas by genome-wide expression profiling.
Suh I; Shibru D; Eisenhofer G; Pacak K; Duh QY; Clark OH; Kebebew E
Ann Surg; 2009 Dec; 250(6):983-90. PubMed ID: 19661783
[TBL] [Abstract][Full Text] [Related]
4. Elevated levels of telomerase activity in malignant pheochromocytoma.
Kubota Y; Nakada T; Sasagawa I; Yanai H; Itoh K
Cancer; 1998 Jan; 82(1):176-9. PubMed ID: 9428495
[TBL] [Abstract][Full Text] [Related]
5. Differential expression and processing of secretogranin II in relation to the status of pheochromocytoma: implications for the production of the tumoral marker EM66.
Guillemot J; Thouënnon E; Guérin M; Vallet-Erdtmann V; Ravni A; Montéro-Hadjadje M; Lefebvre H; Klein M; Muresan M; Seidah NG; Anouar Y; Yon L
J Mol Endocrinol; 2012 Apr; 48(2):115-27. PubMed ID: 22217803
[TBL] [Abstract][Full Text] [Related]
6. Pheochromocytomas, PASS, and immunohistochemistry.
Carlsen E; Abdullah Z; Kazmi SM; Kousparos G
Horm Metab Res; 2009 Sep; 41(9):715-9. PubMed ID: 19718615
[TBL] [Abstract][Full Text] [Related]
7. Malignancy in pheochromocytomas.
Salmenkivi K; Heikkilä P; Haglund C; Arola J
APMIS; 2004 Sep; 112(9):551-9. PubMed ID: 15601303
[TBL] [Abstract][Full Text] [Related]
8. Distinct expression of galectin-3 in pheochromocytomas.
Gimm O; Krause U; Brauckhoff M; Hoang-Vu C; Dralle H
Ann N Y Acad Sci; 2006 Aug; 1073():571-7. PubMed ID: 17102125
[TBL] [Abstract][Full Text] [Related]
9. Expression of chromogranins A, B, and C (secretogranin II) in human adrenal medulla and in benign and malignant pheochromocytomas An immunohistochemical study with region-specific antibodies.
Portela-Gomes GM; Stridsberg M; Grimelius L; Falkmer UG; Falkmer S
APMIS; 2004 Oct; 112(10):663-73. PubMed ID: 15601318
[TBL] [Abstract][Full Text] [Related]
10. [The significance of Ki-67 antigen expression in the distinction between benign and malignant pheochromocytomas].
Feng C; Li HZ; Yan WG; Gao JG; Xu WF; Luo YF; Cao JL
Zhonghua Wai Ke Za Zhi; 2007 Dec; 45(24):1697-700. PubMed ID: 18476530
[TBL] [Abstract][Full Text] [Related]
11. Prognostic indicators of malignancy in adrenal pheochromocytomas: clinical, histopathologic, and cell cycle/apoptosis gene expression analysis.
Strong VE; Kennedy T; Al-Ahmadie H; Tang L; Coleman J; Fong Y; Brennan M; Ghossein RA
Surgery; 2008 Jun; 143(6):759-68. PubMed ID: 18549892
[TBL] [Abstract][Full Text] [Related]
12. Morphometric analysis of benign and malignant adrenal pheochromocytomas.
Hoffman K; Gil J; Barba J; Liu Z; Pertsemlidis D; Kaneko M; Unger P
Arch Pathol Lab Med; 1993 Mar; 117(3):244-7. PubMed ID: 8442669
[TBL] [Abstract][Full Text] [Related]
13. Malignant pheochromocytomas and paragangliomas: molecular signaling pathways and emerging therapies.
Santarpia L; Habra MA; Jiménez C
Horm Metab Res; 2009 Sep; 41(9):680-6. PubMed ID: 19343618
[TBL] [Abstract][Full Text] [Related]
14. Microarray-based comparative genomic hybridization of pheochromocytoma cell lines from neurofibromatosis knockout mice reveals genetic alterations similar to those in human pheochromocytomas.
Powers JF; Tischler AS; Mohammed M; Naeem R
Cancer Genet Cytogenet; 2005 May; 159(1):27-31. PubMed ID: 15860353
[TBL] [Abstract][Full Text] [Related]
15. Development and validation of pheochromocytoma of the adrenal gland scaled score for predicting malignant pheochromocytomas.
Gao B; Meng F; Bian W; Chen J; Zhao H; Ma G; Shi B; Zhang J; Liu Y; Xu Z
Urology; 2006 Aug; 68(2):282-6. PubMed ID: 16904437
[TBL] [Abstract][Full Text] [Related]
16. Pheochromocytoma: presentation, diagnosis and treatment.
Reisch N; Peczkowska M; Januszewicz A; Neumann HP
J Hypertens; 2006 Dec; 24(12):2331-9. PubMed ID: 17082709
[TBL] [Abstract][Full Text] [Related]
17. [Recurrent pheochromocytoma].
Sun Z; Wang Y; Li Z
Zhonghua Wai Ke Za Zhi; 1998 Jan; 36(1):59-60. PubMed ID: 11715546
[TBL] [Abstract][Full Text] [Related]
18. Identification of potential gene markers and insights into the pathophysiology of pheochromocytoma malignancy.
Thouënnon E; Elkahloun AG; Guillemot J; Gimenez-Roqueplo AP; Bertherat J; Pierre A; Ghzili H; Grumolato L; Muresan M; Klein M; Lefebvre H; Ouafik L; Vaudry H; Plouin PF; Yon L; Anouar Y
J Clin Endocrinol Metab; 2007 Dec; 92(12):4865-72. PubMed ID: 17878247
[TBL] [Abstract][Full Text] [Related]
19. [Morphological criteria of the malignancy of pheochromocytoma].
Cheremnykh AA; Kalashnikov SA
Arkh Patol; 1984; 46(12):30-6. PubMed ID: 6395836
[TBL] [Abstract][Full Text] [Related]
20. An immunohistochemical study of pheochromocytomas.
Lloyd RV; Shapiro B; Sisson JC; Kalff V; Thompson NW; Beierwaltes WA
Arch Pathol Lab Med; 1984 Jul; 108(7):541-4. PubMed ID: 6203498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
